The Ottawa Blood Disease Centre provides care for patients with blood disorders within 3 major categories:
The Ottawa Blood Disease Centre treats patients from all over the Champlain LHIN. Annually, this includes:
In early 2013, the Thrombosis clinic moved from the Civic into our new outpatient space, and consolidated all of our benign Hematology clinics from across the city to Module H at the General Campus. These state of the art and brand new ultrasound, lab and clinic facilities will help us to better serve our patients.
Our physicians and staff are devoted to carrying out practice-changing research. We are continually involved in important clinical studies, and our physician/scientists are world-renowned experts in their fields. Our research is conducted through the research arm of The Ottawa Hospital: the Ottawa Hospital Research Institute (OHRI).
2015/16 was another busy year for our Division. Highlights of our¬†high impact papers from this year¬†include:
Carrier M,¬†Lazo-Langner A, Shivakumar S, Tagalakis V, Zarychanski R, Solymoss S, Routhier N, Douketis J, Danovitch K, Lee AY, Le Gal G, Wells P, Corsi DJ, Ramsay T, Coyle D, Chagnon I, Kassam Z, Tao H, Rodger MA; SOME Investigators. Screening¬†for Occult¬†Cancer¬†in¬†Unprovoked¬†Venous Thromboembolism. N Engl J Med.¬†2015 Aug 20;373(8):697-704.
Atkins HL, Bowman M, Allan D, Antsee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O‚ÄôConnor P, Ramsay T, Sabloff M, Walker L, Freedman MS. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet.¬†2016 June 6.
Dreyling M, Jurcazk W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016 Feb 20;387(10020):770-8.¬†Lancet. 2016 Feb 20; 837 (10020): 770-8.
Le Gal G, Righini M, Wells PS.¬† Computed Tomographic Pulmonary Angiography for Pulmonary Embolism.¬† JAMA. 2015 Jul 7;314(1):74-5.
Bryant A,¬†Atkins¬†H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, Hamelin L, Hodgins M, Hopkins H, Huebsch L, McDiarmid S, Sabloff M, Sheppard D, Tay J, Bredeson C. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol. 2016 Jun 1;73(6):652-8.
Skeith L, Carrier M, Kaaja R, Martinelli I, Petroff D, Schleubner E, Laskin CA, Rodger MA. ¬†A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia.¬†¬†¬† Blood. 2016 Mar 31;127(13):1650-5.
Once again, our investigators were granted millions of dollars to advance life-changing research in the area of blood disease. Highlights of grants awarded in 2015-16 include:
CIHR Operating Grant: $407,356.¬† Ito C, Perkins, TJ, Sabloff M, Stanford, WL. The role of PCL2/PRC2 in hematopoietic stem cells and leukemia.
CIHR Community Development Program Grant: >$5,000,000.¬† Kahn SR, Rodger MA et al. CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network.
CIHR Operating Grant: $187,878.¬†Sheppard D,¬†Tay J, Tinmouth A, Allan DS, Beattie SM, Bredeson C, Fergusson DA, Sabloff M, Thavorn K. Platelet Transfusions in Hematopoietic Stem Cell Transplantation -¬†The PATH Study.
CIHR Project Grant: $424,298.¬† Rodger MA, Fergusson DA, Gandara E, Kahn SR, Kearon C, Kovacs MJ, Le Gal G, Ramsay TO, Shivakumar SP, Tagalakis V, Thavom K. StAtins for Venous Even Reduction in Patients with Venous Thromboembolism (SAVER). Top ranking in the 2016 CIHR project competition!
Heart & Stroke Foundation Grant-in-Aid: $255,538.¬† Le Gal G, Anderson D, de Wit K, Kahn S, Kearon C, Ramsay T, Rodger MA, Righini M, Shivakumar S, Wells P. Age-adjusted D-dimer cutoff levels to rule out deep vein thrombosis (The ADJUST-DVT Study).
¬†Honours & Awards